Dernières nouvelles pour Perrigo (NYSE:PRGO) Stock

Perrigo

Perrigo Company

NASDAQ

Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.

Perrigo Co PLC

According to JP Morgan, U.S. large-cap biopharma stocks have underperformed the broader market for two consecutive years, with mixed sentiment shaping investor outlook for 2025.
Despite strong fundamentals and advancements in drug pipelines, factors such as political uncertainty and sector rotation have hindered the sector's performance relative to the S&amp;P 500.
In 2024, biopharma stocks rose by 9.6%, falling short of the S&amp;P 500's 28.5% surge. However, JP Morgan analysts maintain a positive outlook for several key players.
Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), a top pick for the firm, is projected to see continued growth in its diabetes and obesity treatments, <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41622207/eli-lilly-q3-earnings-mounjaro-sales-more-than-double-takes-2-98-billion-hit-to-profit-cuts-annua" rel="noreferrer noopener">Mounjaro and Zepbound</a>. The analyst also pointed to the company's robust pipeline and forecasted double-digit revenue and earnings growth into the 2030s.
Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) has been added to JP Morgan's Analyst Focus List due to the strong potential of its schizophrenia drug, Cobenfy, which could achieve peak sales of $10 billion.
Similarly, Merck &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) and Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) are expected to recover in 2025, following challenges in 2024 related to <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38208816/eye-drug-eylea-price-manipulation-regeneron-faces-us-justice-department-allegations-over-medicare" rel="noreferrer noopener">competitive pressures </a>and regional dynamics <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40168774/mercks-blockbuster-vaccine-gardasil-sales-in-china-analyst-highlights-challenges-an" rel="noreferrer noopener">affecting key products</a>.
Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) is poised for growth with the anticipated mid-2025 launch of lenacapavir <a target="_blank" href="https://www.benzinga.com/quote/GILD" rel="noreferrer noopener">for HIV prevention</a>.
The firm also highlighted AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) for its appealing valuation, supported by strong Skyrizi and Rinvoq sales despite fewer near-term <a target="_blank" href="https://www.benzinga.com/quote/ABBV" rel="noreferrer noopener">pipeline developments</a>.
Animal health stocks are also projected to rebound in 2025. JP Morgan views Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) as the strongest pick in the sector, citing its potential for high single-digit revenue <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41722660/zoetis-q3-earnings-beat-companion-animal-segment-growth-gives-confidence-into-2025-" rel="noreferrer noopener">growth and margin expansion</a>. IDEXX Laboratories, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) is another solid choice, though its performance depends on a r<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41659873/idexx-laboratories-adjusts-guidance-as-q3-revenue-growth-slows-analyst-notes-fewer-" rel="noreferrer noopener">ecovery in veterinary visits</a>. Meanwhile, Elanco Animal Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) faces uncertainties linked to its <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41817807/elanco-animal-q3-earnings-profit-beat-new-products-and-stabilized-business-to-drive" rel="noreferrer noopener">new product launches</a>.
Specialty pharmaceuticals showed early signs of stabilization in 2024, benefiting from improved pricing stability and supply dynamics. Perrigo Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRGO#NYSE">PRGO</a>) and Viatris Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>) are highlighted as promising opportunities, while Teva Pharmaceuticals Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) may face growth challenges despite delivering strong clinical trial <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42561832/teva-pharmaceutical-releases-impressive-phase-2-candidate-data-for-gastro-related-diseases" rel="noreferrer noopener">results this year</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42623487/jp-morgan-defensive-oil-stocks-to-watch-in-2025-amid-70-brent-forecast" target="_blank" rel="noreferrer noopener">Defensive Oil Stocks To Watch In 2025 Amid $70 Brent Forecast: JP Morgan</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Biotech

Large Cap

News

Health Care

Analyst Ratings

Trading Ideas

General

ABBV

ELAN

GILD

IDXX

PRGO

REGN

TEVA

VTRS

Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More

Perrigo Reaches $98M Settlement With D&O Insurers To Resolve Coverage Dispute Over 2015-2017 Securities Litigation, Reimbursing Legal And Settlement Costs Before Year-End

WIIM

Perrigo shares are trading higher. The company reported Q3 financial results.

The Company now expects its fiscal 2024 organic net sales and reported net sales outlooks towards the lower end of its previously stated ranges of organic net sales growth versus the prior year of -3% to -1% and reported net sales growth versus the prior year of -5% to -3%.&nbsp;

Guidance

Perrigo Now Expects FY24 Organic Net Sales And Reported Net Sales Outlooks Towards Lower End Of Its Previously Stated Ranges

Perrigo Reaffirms FY24 Adjusted EPS Outlook Of $2.50 - $2.65, Est $2.57

Perrigo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRGO#NYSE">PRGO</a>) reported quarterly earnings of $0.81 per share which missed the analyst consensus estimate of $0.82 by 1.22 percent. This is a 26.56 percent increase over earnings of $0.64 per share from the same period last year. The company reported quarterly sales of $1.09 billion which missed the analyst consensus estimate of $1.13 billion by 3.29 percent. This is a 3.20 percent decrease over sales of $1.12 billion the same period last year.

Earnings

Earnings Misses

Perrigo Q3 2024 Adj EPS $0.81 Misses $0.82 Estimate, Sales $1.09B Miss $1.13B Estimate

Macro Notification

DARE

PGNY

US State Of Georgia's Supreme Court Reinstates Abortion Ban That Was Blocked By Lower Court

Canaccord Genuity analyst Susan Anderson maintains Perrigo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRGO#NYSE">PRGO</a>) with a Buy and maintains $42 price target.

Price Target

Canaccord Genuity Maintains Buy on Perrigo, Maintains $42 Price Target

Perrigo Company plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRGO#NYSE">PRGO</a>), a leading global provider of Consumer Self-Care Products, today announced a new brand partnership: Good Start&#xAE;1 and Dr. Brown's&#xAE;2 infant formula solutions. Good Start&#xAE;,&nbsp;a trusted infant formula brand for over 50 years, and Dr. Brown's&#xAE;, makers of the No. 1 pediatrician-recommended baby bottle in the U.S.3, share a long-time mission of creating confident feeding experiences for families.
The new Good Start&#xAE; &#x7C; Dr. Brown's&#x2122; portfolio will offer the same trusted infant formula products as the existing Soothe Pro&#x2122; and Gentle Pro&#x2122;, now with refreshed packaging to celebrate the launch of the new partnership. Good Start&#xAE; &#x7C; Dr. Brown's&#x2122; infant formulas offer complete nutrition specially formulated for tolerance concerns.

Perrigo Announces New Brand Partnership, Good Start And Dr. Browns Launch Of Infant Formula Portfolio

Jefferies analyst Keith Devas downgrades Perrigo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRGO#NYSE">PRGO</a>) from Buy to Hold and lowers the price target from $50 to $30.

Downgrades

Jefferies Downgrades Perrigo to Hold, Lowers Price Target to $30

JP Morgan notes that while there&#8217;s a resurgence of interest and excitement in new product launches within the specialty group, including branded and complex generics/biosimilars, investors should be discerning about these opportunities.
The group&#8217;s core fundamentals have strengthened, buoyed by a more stable environment for generic and established brand pricing, which helps mitigate the usual erosion in base business prices.
However, growth in the overall sector remains modest, with most companies experiencing a top-line compound annual growth rate (CAGR) of 0-2%.
Additionally, valuations have recovered, with most stocks now trading near their historical averages.
JP Morgan writes that Teva Pharmaceutical Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) continues to be the primary focus among investors in the group, with sentiment growing more bullish.
The analyst <a target="_blank" href="https://www.benzinga.com/quote/TEVA/analyst-ratings" rel="noreferrer noopener">maintains a Neutral rating</a>, as the market seems to have fully accounted for the company&#8217;s branded pipeline. Additionally, JP Morgan is cautious about Teva&#8217;s U.S. generic business compared to market expectations.
The analyst has given Viatris Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>) <a target="_blank" href="https://www.benzinga.com/quote/VTRS/analyst-ratings" rel="noreferrer noopener">a Neutral rating</a>, citing its stable fundamentals and low valuation amidst uncertainties in business development.
Meanwhile, JP Morgan holds a <a target="_blank" href="https://www.benzinga.com/quote/PRGO/analyst-ratings" rel="noreferrer noopener">more optimistic view</a>, an Overweight rating on Perrigo Co plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRGO#NYSE">PRGO</a>), noting the potential for earnings per share (EPS) to rebound to the low-mid $3 range soon due to currently low market sentiment. With shares currently trading at a significantly lower price than other consumer sector peers, the analyst believes there is substantial potential for an increase in valuation multiples as the recovery progresses.
Similarly, positive <a target="_blank" href="https://www.benzinga.com/quote/AMPH/analyst-ratings" rel="noreferrer noopener">prospects are seen</a> for Amphastar Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>), where the analyst anticipates a promising series of catalysts leading into 2024/2025. Keeps Overweight rating.
JP Morgan is adjusting several ratings, which are relative to each other. The analyst has changed Amneal Pharmaceuticals, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRX#NASDAQ">AMRX</a>) to <a target="_blank" href="https://www.benzinga.com/quote/AMRX/analyst-ratings" rel="noreferrer noopener">Neutral from Underweight</a> and Organon &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGN#NYSE">OGN</a>) to <a target="_blank" href="https://www.benzinga.com/quote/OGN/analyst-ratings" rel="noreferrer noopener">Underweight from Neutral</a>.
For Amneal, the company&#8217;s success in launching new products suggests the potential for improved financial forecasts, which could bolster the stock.
Conversely, Organon&#8217;s stock price has increased 60% year-to-date. Although its valuation still appears low, the recent price surge suggests more attractive opportunities within the sector may exist.
Price Action: OGN stock is down 2.95% at $20.73, and AMRX stock is down 1.42% at $8.33 at last check Friday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40752830/robinhood-shifted-from-meme-stock-to-market-contender-amid-new-products-and-global-" target="_blank" rel="noreferrer noopener">Robinhood Shifted From Meme Stock To Market Contender Amid New Products And Global Expansion: Analyst Upgrades Stock</a>.</li>
</ul>

Equities

Reiteration

AMPH

AMRX

JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability

<a href="https://truthsocial.com/@realDonaldTrump/posts/113012083325505976" title="https://truthsocial.com/@realDonaldTrump/posts/113012083325505976">https://truthsocial.com/@realDonaldTrump/posts/113012083325505976</a>

Politics

Former President Donald J. Trump Posts On Truth Social "My Administration will be great for women and their reproductive rights."

Fiscal Year 2024&nbsp;Outlook:
<ul>
<li>Company updates its fiscal 2024 organic net sales growth&nbsp;outlook&nbsp;versus the prior year to&nbsp;-3%&nbsp;to&nbsp;-1%, from&nbsp;+1%&nbsp;to&nbsp;+3%, and total net sales growth&nbsp;outlook&nbsp;to&nbsp;-5%&nbsp;to&nbsp;-3%&nbsp;from flat, due primarily to lower seasonal demand experienced in the first half of 2024 and expected lower distribution in&nbsp;U.S. store brand in the second half of 2024.
	&nbsp;&nbsp;</li>
<li>The Company reaffirms its fiscal 2024 adjusted diluted EPS&nbsp;outlook&nbsp;of&nbsp;$2.50-$2.65, as increased profitability from faster than anticipated recovery in the infant formula business, improved product mix and lower selling expenses are expected to be offset by flow-through from the updated net sales&nbsp;outlook.&nbsp;</li>
</ul>

Perrigo Company Reaffirms Fiscal 2024 Adjusted Diluted EPS Outlook Of $2.50-$2.65 Vs. $2.25 Estimate

Perrigo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRGO#NYSE">PRGO</a>) reported quarterly earnings of $0.53 per share which beat the analyst consensus estimate of $0.51 by 3.92 percent. This is a 15.87 percent decrease over earnings of $0.63 per share from the same period last year. The company reported quarterly sales of $1.07 billion which missed the analyst consensus estimate of $1.16 billion by 8.10 percent. This is a 10.65 percent decrease over sales of $1.19 billion the same period last year.

Earnings Beats

Perrigo Q2 Adj $0.53 Beats $0.46 Estimate, Sales $1.07B Miss $1.16B Estimate

AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) has petitioned the U.S. Supreme Court to protect its corporate records, arguing that a lower court ruling threatens the <a href="https://drupal-cloudfront.benzinga.com/topic/legal">confidentiality of attorney communications</a>.
The pharmaceutical company is seeking to overturn a decision by the 3rd U.S. Circuit Court of Appeals, stating that filing a sham patent-infringement lawsuit could override attorney-client privilege.
The case stems from allegations in the Philadelphia federal court where drug wholesalers, including Cencora Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) (formerly AmerisourceBergen) and McKesson Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), claim they were overcharged for the testosterone replacement drug AndroGel.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39480818/abbvies-parkinsons-disease-therapy-hits-fda-roadblock" rel="noreferrer noopener">AbbVie&#8217;s Parkinson&#8217;s Disease Therapy Hits FDA Roadblock</a>.
The wholesalers allege that AbbVie filed a baseless patent infringement lawsuit against Perrigo Company plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRGO#NYSE">PRGO</a>) in 2011 to delay the release of a cheaper generic version of AndroGel.
In February, the 3rd U.S. Circuit Court of Appeals ruled that AbbVie must provide the wholesalers with 19 documents containing notes from in-house attorneys and memos from outside legal counsel regarding the Perrigo lawsuit.
The court reasoned that the sham patent case constituted fraudulent activity, thus triggering the crime-fraud exception to attorney-client privilege.
AbbVie contends that this ruling significantly broadens the scope of the crime-fraud exception and conflicts with the interpretation of &#8220;fraud&#8221; by the Washington, D.C.-based Federal Circuit, which specializes in intellectual property litigation. AbbVie warned that the decision could encourage plaintiffs to file antitrust lawsuits by alleging that related patent litigation was a sham, potentially allowing them to access internal attorney records.
The Supreme Court petition is part of AbbVie&#8217;s long-standing legal battle over AndroGel. The product saw annual U.S. net sales exceeded $1 billion before generic versions entered the market in 2015.
A Reuters report added that the wholesalers&#8217; case was initiated in 2019. It followed a Federal Trade Commission lawsuit against AbbVie that has since been resolved.
Price Action: ABBV shares are up 0.45% at $170.68 at last check Friday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/04/38300021/is-your-botox-real-or-fake-counterfeit-boxes-circulate-for-widely-used-antiwrinkle-treatment-cdc-" target="_blank" rel="noreferrer noopener">Is Your Botox Real Or Fake? Counterfeit Boxes Circulate For Widely Used Antiwrinkle Treatment, CDC And FDA Investigate Harmful Reactions</a>.</li>
</ul>

Legal

AbbVie Appeals To Supreme Court Over Attorney-Client Privilege In 'Long-Standing' AndroGel Case

Piper Sandler analyst Korinne Wolfmeyer maintains Perrigo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRGO#NYSE">PRGO</a>) with a Overweight and lowers the price target from $36 to $35.

Piper Sandler Maintains Overweight on Perrigo, Lowers Price Target to $35

Macro Economic Events

Economics

Iowa's Highest Court Allows State To Enforce Ban On Most Abortions After About Six Weeks Of Pregnancy

U.S. Supreme Court Allows, For Now, Abortions To Be Performed In Idaho In Cases Of Medical Emergencies For Pregnant Women

- Reuters Citing Bloomberg Reporter On X, Citing Copy Of Opinion Briefly Posted On Court's Website

U.S. Supreme Court Is Poised To Allow Abortions In Medical Emergencies In Idaho

Supreme Court Upholds Unrestricted Access To Mifepristone Abortion Pill

Perrigo Q3 2024 Earnings Preview

Here's the major earnings before the open tomorrow

Perrigo Non-GAAP EPS of $0.81 in-line, revenue of $1.1B misses by $30M

Reports Q3 revenue $1.09B, consensus $1.12B. President and CEO, Patrick Lockwood-Taylor commented, "During the third quarter, we made significant p...

Perrigo reports Q3 adjusted EPS 81c, consensus 81c

The company said, "The Company expects its fiscal 2024 organic net sales and total net sales outlook to be towards the lower end of their previousl...

Perrigo backs FY24 adjusted EPS view $2.50-$2.65, consensus $2.56

Perrigo Company plc (PRGO) Q3 2024 Earnings Call Transcript

Perrigo Company: Great Combination Of Future Growth With A Low Valuation

Dividend Champion, Contender, And Challenger Highlights: Week Of November 24

Wolfe's short ideas: Companies with potential dividend cuts

Dividend Champion, Contender, And Challenger Highlights: Week Of December 15

ABUS

ADRNY

ALLE

ALSN

AMCR

AMGN

APAM

APLO

ARLP

ATHM

AUDC

AVGO

BCPC

BLMN

BMWYY

BOKF

BSVN

CABO

CALM

CARR

CBOE

CBSH

CCBG

CCFN

CCOI

CELH

CGNX

CINF

CIVI

CLBT

CNDT

CNOB

CPKF

CRAI

CSGS

CTRA

CTSH

CTVA

CWEN

DMLP

EBAY

EHTH

ENOV

ENSG

EPRT

ERIE

ESNT

EVRG

EXPD

EXPO

FCFS

FLNG

FMBH

FOLD

FRME

FXNC

GCBC

GOGL

GOLF

GWRS

HASI

HENKY

HESM

HONT

HTBI

HUBB

HWKN

INVH

IONS

IOSP

JJSF

JKHY

KALU

KFRC

KLIC

KNSL

KNTK

LAND

LARK

LCII

LCNB

LNTH

MATW

MBCN

MBWM

MCFT

MGEE

MKTX

MOGO

MPLX

MSCI

MSEX

MUSA

NBHC

NBTB

NDAQ

NEON

NRIM

NXST

ODFL

OESX

OFLX

OLED

OTEX

PAYX

PDCO

PERI

PFGC

PFIS

POOL

POWI

PPBI

PPLL

PSTL

PTEN

Comments

Perrigo

Actualités

Dernières nouvelles pour Perrigo (NYSE:PRGO) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL